Published date: Sep 26 2024

Journal Title: West Kazakhstan Medical Journal

Issue title: West Kazakhstan Medical Journal: Volume 66 Issue 3

Pages: 255–266

DOI: 10.18502/wkmj.v66i3.16040

Kulman Nyssanbayevawhereaboutskaz@gmail.com

Venera Abdulla

Zhanar Andassova

Natalya Glushkova

Anabolic-androgenic steroids (AAS) are synthetic variations of the male sex hormone testosterone. They mimic testosterone’s effects, primarily promoting muscle growth (anabolic effects) and enhancing male traits (androgenic effects). The misuse of AAS has extended beyond high-performance athletes and is now prevalent among the general population, particularly among fitness and gym enthusiasts. Epidemiological data highlight the widespread abuse of these substances, driven by the aspiration to enhance muscle mass, strength, and overall physical performance. The misuse of AAS in the fitness industry poses significant health risks and ethical concerns. This review highlights the prevalence, consequences, and prevention strategies related to AAS misuse in the fitness industry.

[1] Kanayama G, Pope HG. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018 Mar 15;464:4–13.

[2] Korkia P. Anabolic-androgenic steroids and their uses in sport and recreation. J Subst Use. 1997;2(3):131–135.

[3] Henning AD, Dimeo P. The new front in the war on doping: Amateur athletes. Int J Drug Policy Elsevier B.V. 2018;51:128–136.

[4] Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis [Internet]. Ann Epidemiol. Elsevier Inc. 2014;24: 383– 398. [cited 2021 Jan 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/24582699/

[5] Parkinson AB, Evans NA. Anabolic androgenic steroids: A survey of 500 users. Med Sci Sports Exerc. 2006 Apr;38(4):644–651. [cited 2021 Jan 24] Available from: http://journals.lww.com/00005768-200604000-00006

[6] Andreasson J, Johansson T. Fitness doping. Fitness Doping. 2020.

[7] Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333–340.

[8] Evans NA. Gym and tonic: A profile of 100 male steroid users. Br J Sports Med. 1997;31(1):54–58.

[9] Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis. Ann Epidemiol. Elsevier Inc. 2014;24:383–398.

[10] Gwizdek K, Brzek A, Bak-Sosnowska M, Dittfeld A, Knapik A, Ziaja D. The use of steroids by gym athletes: An attempt to diagnose the problem scale and possible causes. J Sports Med Phys Fitness. 2018;58(6):880–888.

[11] Lykhonosov MP, Babenko AY. The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint Petersburg. Probl Endokrinol (Mosk). 2019;65(1):19–30.

[12] Lafta RK, Mohammad GA. Anabolic Supplements abuse among athletes in Baghdad Gyms. Iraqi J Community Med. 2012;2012(4):268–273.

[13] Arora S. Knowledge, attitude and practices regarding anabolic steroids among adults. Nurs Midwifery Res J. 2019;15.1( June):40–48.

[14] Tara F, Lotfalizadeh M, Moeindarbari S. Electronic Physician (ISSN: 2008-5842). Electron Physician. 2016;8(10):3057–3061. Available from: http://scielo.isciii.es/pdf/albacete/v3n2/especial2.pdf

[15] Alsaeed I, Alabkal JR. Usage and perceptions of anabolic-androgenic steroids among male fitness centre attendees in Kuwait - A cross-sectional study. Subst Abus Treat Prev Policy. 2015;10(1):1–6. Available from: http://dx.doi.org/10.1186/s13011-015-0030-5

[16] Sagoe D, McVeigh J, Bjørnebekk A, Essilfie MS, Andreassen CS, Pallesen S. Polypharmacy among anabolicandrogenic steroid users: A descriptive metasynthesis. Subst Abus Treat Prev Policy. 2015;10(1).

[17] Bahrke MS. Performance-enhancing substance misuse in sport: Risk factors and considerations for success and failure in intervention programs. Subst Use Misuse. 2012;47(13–14):1505–1516.

[18] Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: A review. Fundam Clin Pharmacol. 2005;19(1):27–44.

[19] Wu C, Kovac JR. Novel uses for the anabolic androgenic steroids nandrolone and oxandrolone in the management of male health. Curr Urol Rep. 2016;17(10):1–7. Available from: http://dx.doi.org/10.1007/s11934-016- 0629-8

[20] Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.

[21] Melnik BC. Androgen abuse in the community. Current Opinion in Endocrinology, Diabetes and Obesity. 2009;16:218–223.

[22] Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: A regional study. Eur J Intern Med. 2006 Nov [cited 2021 Jan 19];17(7):479–484. Available from: https://pubmed.ncbi.nlm.nih.gov/17098591/

[23] Stilger VG, Yesalis CE. Anabolic-androgenic steroid use among high school football players. J Community Health. 1999;24(2):131–145. [cited 2021 Jan 19] Available from: https://pubmed.ncbi.nlm.nih.gov/10202692/

[24] Bonnecaze AK, O’Connor T, Aloi JA. Characteristics and attitudes of men using anabolic androgenic steroids (AAS): A survey of 2385 men. Am J Mens Health. 2020;14(6).

[25] Bilard J, Ninot G, Hauw D. Motives for illicit use of doping substances among athletes calling a national antidoping phone-help service: An exploratory study. Subst Use Misuse. 2011;46(4):359–367.

[26] Piacentino D, Kotzalidis G, Casale A, Aromatario M, Pomara C, Girardi P, et al. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Curr Neuropharmacol. 2014;13(1):101–121.

[27] Kimergard A. A qualitative study of anabolic steroid use amongst gym users in the United Kingdom: Motives, beliefs and experiences. J Subst Use. 2015;20(4):288–294.

[28] Harvey O, Keen S, Parrish M, Van Teijlingen E. Support for people who use anabolic androgenic steroids: A systematic scoping review into what they want and what they access. BMC Public Health. 2019;19(1):1–13.

[29] Haerinejad MJ, Ostovar A, Farzaneh MR, Keshavarz M. The prevalence and characteristics of performanceenhancing drug use among bodybuilding athletes in the south of Iran, Bushehr. Asian J Sports Med. 2016 Sep 1;7(3).

[30] Striegel H, Simon P, Frisch S, Roecker K, Dietz K, Dickhuth HH, et al. Anabolic ergogenic substance users in fitness-sports: A distinct group supported by the health care system. Drug Alcohol Depend. 2006 Jan 4;81(1):11–19.

[31] Torrisi M, Pennisi G, Russo I, Amico F, Esposito M, Liberto A, et al. Sudden cardiac death in anabolic-androgenic steroid users: A literature review. Med. 2020;56(11):1–19.

[32] Juhn MS, Tarnopolsky M. Potential side effects of oral creatine supplementation: A critical review. Clinical Journal of Sport Medicine. 1998;8:298–304.

[33] Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Positive and negative side effects of androgen abuse. The HAARLEM study: A one-year prospective cohort study in 100 men. Scand J Med Sci Sport. 2021;31(2):427– 438.

[34] Pope HG, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: A controlled study of 160 athletes. Arch Gen Psychiatry. 1994;51(5):375–382 [cited 2021 Jan 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/8179461/

[35] Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolicandrogenic steroid dependence [Internet]. Available from: http://caesar.sheridan.com/reprints/

[36] van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117–123. Available from: http://dx.doi.org/10.1016/j.yrtph.2010.02.001

[37] Pope HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performanceenhancing drugs: An endocrine society scientific statement. Endocrine Reviews. Endocrine Society. 2014;35:341– 375. [cited 2021 Apr 18]. Available from: /pmc/articles/PMC4026349/

[38] Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping.

[39] Cope MR, Ali A, Bayliss NC. Biceps rupture in bodybuilders: Three case reports of rupture of the long head of the biceps at the tendon-labrum junction. J Shoulder Elb Surg. 2004 Sep;13(5):580–582. [cited 2021 Jan 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/15383821/

[40] Kanayama G, Deluca J, Meehan WP, Hudson JI, Isaacs S, Baggish A, et al. Ruptured tendons in anabolicandrogenic steroid users. Am J Sports Med. 2015 Nov 1;43(11):2638–2644. [cited 2021 Apr 18]. Available from: /pmc/articles/PMC5206906/

[41] Sollender JL, Rayan GM, Barden GA. Triceps tendon rupture in weight lifters. J Shoulder Elb Surg. 1998;7(2):151– 153. [cited 2021 Jan 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/9593095/

[42] Jones IA, Togashi R, Hatch GFR, Weber AE, Vangsness CT. Anabolic steroids and tendons: A review of their mechanical, structural, and biologic effects. J Orthop Res. 2018;36(11):2830–2841.

[43] Pope HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performanceenhancing drugs: An endocrine society scientific statement. Endocrine Reviews. Endocrine Society. 2014;35:341– 375.

[44] Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolicandrogenic steroid dependence. Pharmacotherapy. 2012 Oct;32(10):910–919. [cited 2021 Jan 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/23033230/

[45] Molero Y, Gripenberg J, Bakshi AS. Effectiveness and implementation of a community-based prevention programme targeting anabolic androgenic steroid use in gyms: Study protocol of a quasiexperimental control group study. BMC Sports Sci Med Rehabil. 2016 Nov 17;8(1).

[46] Pasquarella C, Pompili M, Valeriani F, Morgado M, Milicia GM, Veronesi L, et al. The prevention of doping and the improper use of drugs and food supplements in sports and physical activities: A survey on the activity of the prevention departments of Italian local health authorities. Ann di Ig. 2019;31(6):533–547.

[47] Heuberger JAAC, Cohen AF. Review of WADA prohibited substances: Limited evidence for performanceenhancing effects. Sport Med. 2019;49(4):525–539. Available from: https://doi.org/10.1007/s40279-018-1014-1

[48] Gatterer K, Gumpenberger M, Overbye M, Streicher B, Schobersberger W, Blank C. An evaluation of prevention initiatives by 53 national anti-doping organizations: Achievements and limitations. J Sport Heal Sci. 2020 May 1;9(3):228–239.

[49] Fallace P, Aiese P, Bianco E, Bolognini I, Costa MP, Esposito R, et al. Peer education strategies for promoting prevention of doping in different populations. Ann di Ig. 2019;31(6):556–575.

[50] Halliburton AE, Fritz MS. Health beliefs as a key determinant of intent to use anabolic-androgenic steroids (AAS) among high-school football players: implications for prevention. Int J Adolesc Youth. 2018;23(3):269–280. Available from: http://doi.org/10.1080/02673843.2017.1344928